States Are Toughening Up Privacy Laws for At-Home DNA Tests
By Emily Mullin,
Wired
| 10. 21. 2021
IF YOU’VE EVER spit into a plastic tube or swabbed your cheek and mailed your saliva away to learn about your ancestry or health risks, you might have assumed that the company analyzing your DNA is legally required to keep your genetic data private. But you’d be wrong.
The Health Insurance Portability and Accountability Act, known as HIPAA, protects individuals’ medical information when it's handled by doctors, hospitals, and health insurance companies. This applies to genetic tests ordered by your doctor but not to those you can buy online directly from companies like 23andMe and Ancestry because these kits aren’t considered medical tests. As a result, the companies have largely operated in a legal gray area. Firms write their own privacy policies that customers agree to when they purchase a kit, but the companies can change these policies at any time.
That’s a problem, since genetic data can reveal all sorts of sensitive information about you—your ethnicity, your family connections, and even your likelihood of developing Alzheimer’s disease or certain cancers. Law enforcement officers are increasingly using consumer...
Related Articles
By Emily Baumgaertner Nunn, The New York Times | 09.08.2026
It is one of biology’s most ingenious rhythms: Every baby is born young. No matter how much wear and tear their parents’ DNA accumulated over their lifetimes, reproduction erases the molecular scars, handing a clean slate to the next generation...
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Jessica Hamzelou, MIT Technology Review | 07.23.2026
When it comes to organ donation, time is everything. As soon as an organ has been carefully removed from a donor’s body, it starts to deteriorate. Surgeons have a matter of hours to get it into a recipient. Leave...